These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 10532552

  • 1. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors.
    Dodson SF, Bonham CA, Geller DA, Cacciarelli TV, Rakela J, Fung JJ.
    Transplantation; 1999 Oct 15; 68(7):1058-61. PubMed ID: 10532552
    [Abstract] [Full Text] [Related]

  • 2. Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy.
    Yu AS, Vierling JM, Colquhoun SD, Arnaout WS, Chan CK, Khanafshar E, Geller SA, Nichols WS, Fong TL.
    Liver Transpl; 2001 Jun 15; 7(6):513-7. PubMed ID: 11443579
    [Abstract] [Full Text] [Related]

  • 3. Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation.
    Holt D, Thomas R, Van Thiel D, Brems JJ.
    Arch Surg; 2002 May 15; 137(5):572-5; discussion 575-6. PubMed ID: 11982471
    [Abstract] [Full Text] [Related]

  • 4. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
    Prakoso E, Strasser SI, Koorey DJ, Verran D, McCaughan GW.
    Clin Transplant; 2006 May 15; 20(3):369-73. PubMed ID: 16824156
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors.
    Roque-Afonso AM, Feray C, Samuel D, Simoneau D, Roche B, Emile JF, Gigou M, Shouval D, Dussaix E.
    Gut; 2002 Jan 15; 50(1):95-9. PubMed ID: 11772974
    [Abstract] [Full Text] [Related]

  • 7. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine.
    Nery JR, Nery-Avila C, Reddy KR, Cirocco R, Weppler D, Levi DM, Nishida S, Madariaga J, Kato T, Ruiz P, Schiff E, Tzakis AG.
    Transplantation; 2003 Apr 27; 75(8):1179-86. PubMed ID: 12717200
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors.
    Chen YS, Wang CC, de Villa VH, Wang SH, Cheng YF, Huang TL, Jawan B, Chiu KW, Chen CL.
    Clin Transplant; 2002 Dec 27; 16(6):405-9. PubMed ID: 12437618
    [Abstract] [Full Text] [Related]

  • 11. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.
    Castells L, Vargas V, Rodríguez F, Allende H, Buti M, Sánchez-Avila JF, Jardí R, Margarit C, Pumarola T, Esteban R, Guardia J.
    Liver Transpl; 2002 Oct 27; 8(10):892-900. PubMed ID: 12360430
    [Abstract] [Full Text] [Related]

  • 12. Active immunization for prevention of De novo hepatitis B virus infection after adult living donor liver transplantation with a hepatitis B core antigen-positive graft.
    Wang SH, Loh PY, Lin TL, Lin LM, Li WF, Lin YH, Lin CC, Chen CL.
    Liver Transpl; 2017 Oct 27; 23(10):1266-1272. PubMed ID: 28691231
    [Abstract] [Full Text] [Related]

  • 13. Liver grafts from anti-hepatitis B core positive donors: a systematic review.
    Cholongitas E, Papatheodoridis GV, Burroughs AK.
    J Hepatol; 2010 Feb 27; 52(2):272-9. PubMed ID: 20034693
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.
    Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, Dawson S, Goldstein L, Yersiz H, Farmer DG, Ghobrial RM, Busuttil RW, Martin P.
    Liver Transpl; 2000 Nov 27; 6(6):741-8. PubMed ID: 11084061
    [Abstract] [Full Text] [Related]

  • 17. Case report of lamivudine-resistant hepatitis B virus infection post liver transplantation from a hepatitis B core antibody donor.
    Yen RD, Bonatti H, Mendez J, Aranda-Michel J, Satyanarayana R, Dickson RC.
    Am J Transplant; 2006 May 27; 6(5 Pt 1):1077-83. PubMed ID: 16611347
    [Abstract] [Full Text] [Related]

  • 18. Does lamivudine prophylaxis eradicate persistent HBV DNA from allografts derived from anti-HBc-positive donors?
    Loss GE, Mason AL, Nair S, Blazek J, Farr G, Guo L, Cohen AJ, Eason JD.
    Liver Transpl; 2003 Dec 27; 9(12):1258-64. PubMed ID: 14625825
    [Abstract] [Full Text] [Related]

  • 19. Infectivity of hepatic allografts with antibodies to hepatitis B virus.
    Dodson SF, Issa S, Araya V, Gayowski T, Pinna A, Eghtesad B, Iwatsuki S, Montalvo E, Rakela J, Fung JJ.
    Transplantation; 1997 Dec 15; 64(11):1582-4. PubMed ID: 9415560
    [Abstract] [Full Text] [Related]

  • 20. Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation.
    Karasu Z, Ozacar T, Akyildiz M, Demirbas T, Arikan C, Kobat A, Akarca U, Ersoz G, Gunsar F, Batur Y, Kilic M, Tokat Y.
    Antivir Ther; 2004 Dec 15; 9(6):921-7. PubMed ID: 15651751
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.